RephImmune Biotechnology Inc. is a Boston-incubated startup, officially incorporated in Taiwan in 2023.

Our skilled team, comprising experts with FDA-approved product credentials, is dedicated to advancing innovative cell and gene therapies.

We are currently in a preclinical stage with fully self-innovated patent.

We have innovated a novel genetically engineered immune cell therapy for the treatment of solid tumors, focusing on late-stage ovarian cancer as our initial target